Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

Goldman Small Cap Research Publishes New Research Report on First Wave BioPharma, Inc.

Accesswire March 31, 2022

First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

GlobeNewswire March 28, 2022

First Wave BioPharma to Participate in Maxim's 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

First Wave BioPharma to Participate in "Fireside Chat" at the 34th Annual Roth Conference

GlobeNewswire March 8, 2022

First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference

GlobeNewswire March 3, 2022

First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire March 2, 2022

First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer

GlobeNewswire March 1, 2022

First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

GlobeNewswire February 28, 2022

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

GlobeNewswire February 7, 2022

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

GlobeNewswire January 13, 2022

First Wave BioPharma Announces Further Adjournment of Annual Meeting

GlobeNewswire January 7, 2022

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

GlobeNewswire January 6, 2022

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

GlobeNewswire January 4, 2022

First Wave BioPharma Announces Adjournment of Annual Meeting

GlobeNewswire December 17, 2021

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

GlobeNewswire December 13, 2021

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

GlobeNewswire December 9, 2021

First Wave BioPharma's CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference

GlobeNewswire December 6, 2021

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections

GlobeNewswire November 30, 2021

First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio

GlobeNewswire November 16, 2021

First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis

GlobeNewswire October 21, 2021